Tassos Georgiadis
Company: MeiraGTx
Job title: Vice President - Preclinical Development
Bio:
Tassos has been working on retinal gene therapy for 20 years. He has developed AAV vectors for a range of indications that are currently in clinical development (Ph1/2 and Ph3). He is currently VP Preclinical Development at MeiraGTx establishing a multi-platform assessment strategy for drug product candidate screening, with a focus on CNS and retina.
Seminars:
Leveraging the Latest Retinal Organoid Developments 10:10 am
What are the advantages of using iPSC-derived retinal organoids over traditional animal model studies? Understanding the latest developments for their use in gene therapy studies How close are we to seeing FDA guidance documents on retinal organoids?Read more
day: Conference Day Two